1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)

Background

Efficacy demonstration of a unique peptide-based immunotherapy as potent approach for cancer treatment. This strategy relies on the activation of commensal-specific T cells which cross-react against peptides derived from Tumor-Associated Antigens (TAAps) found in various solid tumors, including glioblastoma, adrenocortical carcinoma and colorectal cancer. The same strategy is also used to target lineage-specific markers in hematologic cancers such as B cell malignancies.

Methods

The gut microbiota has the outstanding ability of regulating the human immune system through commensal antigens. Since specific microbiota peptides exhibit significant homology with particular TAAs, the full potential of cross-reactive CD8+ T cells that recognize both commensal peptides and poorly immunogenic tumor antigens can thus be harnessed against tumor cells. We identified a specific set of commensal derived peptides, referred to as OncoMimics™ (OMP) peptides, which elicit cross-reactive cytotoxic CD8+ T cell responses against TAAps owing to their strong sequence homology. The capacity of these OMPs to induce TAAps-specific cross-reactive CD8+ T cell responses in humans is evaluated through peptide-MHC multimer staining and flow cytometry-based cytotoxic assays.

Results

Experiments conducted on human peripheral blood mononuclear cells (PBMCs) demonstrate that OMPs can be recognized by CD8 T cells in a significant proportion of healthy individuals. Upon in vitro stimulation, OMPs induce the expansion of CD8+ T cells that recognize homologous peptides derived from tumor antigen targets. Importantly, these T cells display cytotoxic capabilities against tumor cells presenting the corresponding TAAps on their surface. Further support for this approach comes from ongoing clinical trials, since we displayed that CD8+ T cells from indolent Non-Hodgkin Lymphoma (iNHL) patients treated with EO2463 immunotherapy (SIDNEY, EONHL1–20 phase 1/2 trial) are cytotoxic against TAA protein-expressing tumor cell lines.¹

Conclusions

These data provide compelling evidence that OncoMimic peptides sharing a high degree of homology with TAAps can be utilized to generate an effective anti-tumor immune response.

Reference

https://www.enterome.com/clinical-trials/

Ethics Approval

Buffy coats from healthy donors were provided from the Blood Bank (Etablissement français du sang (EFS)) of Rungis. This study was performed according to established ethical guidelines, and all blood donors gave informed consent. Patient cells are coming from the ongoing EONHL1–20 phase 1/2 trial.